Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 20,529 Shares

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. bought 20,529 shares of Abrdn Life Sciences Investors stock in a transaction on Wednesday, April 24th. The stock was acquired at an average cost of $13.12 per share, with a total value of $269,340.48. Following the acquisition, the insider now owns 2,807,724 shares of the company’s stock, valued at approximately $36,837,338.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 22nd, Saba Capital Management, L.P. acquired 2,022 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $12.88 per share, with a total value of $26,043.36.
• On Thursday, April 18th, Saba Capital Management, L.P. bought 81,738 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average cost of $12.80 per share, with a total value of $1,046,246.40.

Abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL opened at $12.97 on Friday. The business’s 50 day simple moving average is $13.49 and its 200-day simple moving average is $13.10. Abrdn Life Sciences Investors has a 12 month low of $11.34 and a 12 month high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 12.03%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend was Wednesday, February 21st.

Institutional Trading of Abrdn Life Sciences Investors

Large investors have recently bought and sold shares of the company. Future Financial Wealth Managment LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the 1st quarter worth about $27,000. Matisse Capital acquired a new position in Abrdn Life Sciences Investors during the fourth quarter worth about $135,000. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 60.4% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock valued at $136,000 after purchasing an additional 3,811 shares in the last quarter. Eudaimonia Partners LLC acquired a new stake in shares of Abrdn Life Sciences Investors in the first quarter valued at approximately $142,000. Finally, International Assets Investment Management LLC grew its position in shares of Abrdn Life Sciences Investors by 3,424.5% in the fourth quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock valued at $149,000 after purchasing an additional 10,753 shares during the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.